How do 'stimulants' reduce hyperactivity in children and adults? How can drugs which raise extracellular dopamine result in psychomotor slowing of hyperactive children when dopamine is known to enhance motor activity, such as in Parkinson's disease? These apparent paradoxes are the focus of this brief review on the mechanism of action of stimulant medications used in the treatment of children, and of an increasing number of adults who meet diagnostic criteria for attention deficit hyperactivity disorder.
The use of stimulant medicatons for attention deficit hyperactivity disorder has almost tripled since 1990. The increased usage presumably stems from the wider recognition and the more criterion-based diagnosis of this disorder, occurring in 2-6% of children in North America, as well as from the expanding knowledge that such stimulant medications continue to be effective over many months or years, well into adulthood, and do not produce long-term adverse effects.
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Chemistry
The medications commonly used for attention deficit hyperactivity disorder are methylphenidate, dextroamphetamine, and pemoline, which, along with cocaine, stimulate psychomotor activity. The chemical structures of these compounds are shown in Figure 1 , with dopamine included for comparison. All these drugs act on neurons to promote the release of dopamine or to block the transport of dopamine by blocking the dopamine transporter.
It has long been thought that the nitrogen atom is needed for amine-containing drugs to bind to the biological target, 5 but Madras and colleagues have recently shown that the nitrogen atom may be replaced by either an oxygen atom 6, 7 or a carbon atom (BK Madras et al, to be published), and the cocaine-like drugs will still selectively block the dopamine transporter target in vitro. (Although the nitrogen and oxygen atoms each have lone pair electrons which can form a hydrogen bond with the dopamine transporter, 5, 7 the carbon atom does not, thus raising considerably interesting theoretical problems as to how such carbon-based molecules bind to the dopamine transporter.)
Because methylphenidate has two asymmetric carbon atoms (asterisks in Figure 1 ), this drug has four different forms, (+)-and (−)-erythromethylphenidate, and (+)-and (−)-threomethylphenidate. 8 The methylphenidate used clinically is a 50:50 mixture of (+)-and (−)-threomethylphenidate, and is ten-fold to one hundredfold more potent on various tissues compared to the (±)-erythro-form. 8 
Behavioral pharmacology
High doses of l-DOPA* (which is converted to dopamine in the brain) stimulate locomotion in normal rodents as well as in Parkinson patients by increasing brain dopamine. 9 This effect is observed despite the loss of 96% to more than 99% of the dopamine content and the dopamine terminals in the Parkinson putamen in the end stages of the disease. 10, 11 Low doses of l-DOPA, however, as well as other dopamine-like agonists, reduce locomotor activity in animals. [12] [13] [14] This biphasic action also occurs with dextroamphetamine or methylphenidate in animals which are either spontaneously active [15] [16] [17] or made hyperactive by a neonatal lesion. 18 An example of such biphasic action of dextroamphetamine (d-amphetamine) is shown in Figure 2 . Figure 1 Chemical structures of medications used clinically to reduce hyperactivity, and their similarity to dopamine and cocaine. Each asterisk indicates an asymmetric carbon atom which results in two chemical forms. Thus, amphetamine has two forms, (+)-and (−)-, while methylphenidate has two asymmetric carbon atoms, resulting in four forms, wherein the mixed form (±)-threo-methylphenidate is used clinically. Although each stimulant contains a nitrogen atom which can bond to the dopamine transporter target, Madras and colleagues have shown that the nitrogen atom can be replaced by an oxygen atom 6, 7 or a carbon atom (Madras et al, to be published) while still retaining the drug's potency in vitro.
Clinical doses
Similar to the situation outlined above for animals, the stimulant medications also elicit a biphasic action in humans, with low doses reducing locomotor activity Figure 2 Biphastic action of dextroamphetamine (damphetamine) on mice, eliciting hypolocomotion at low doses (i.p.), but stimulating motor activity at high doses. The spontaneous motor activity was measured using Stoelting sensor activity meters. The different strains of mice, BALB/cJ, C3H/HeJ, and A/J, had been obtained from Jackson Laboratories (Bar Harbor, ME, USA). The asterisks indicate locomotor activity statistically significantly different from control (P Ͻ 0.02). Adapted from Ref. 15. and distractibility, and high doses (or overdosage) causing sleeplessness and other symptoms of excessive central nervous system stimulation. The clinical dose 2, 19 range for dextroamphetamine is between 0.2 and 0.6 mg kg −1 (given twice a day), which happens to be similar to that for slowing animal locomotion, as shown in Figure 2 . The dose range for methylphenidate is 0.3 mg kg −1 to 0.6 mg kg −1 2,3,20 (given twice a day), while that for pemoline is 38-150 mg per day. Pemoline is titrated up from 19 mg day −1 to a maximum of 2 mg kg −1 day −1 in adults, although for children the daily doses frequently approach or exceed 3 mg kg
Regulation of synaptic dopamine levels
The dopamine transporter and the presynaptic receptors for dopamine (autoreceptors) are two key regulators of extracellular levels of dopamine in the synaptic space. The release of dopamine (into the extracellular synaptic space) from dopamine-containing neurons occurs in a pulsatile manner during nerve impulses, and in a steady non-pulsatile manner during rest intervals between nerve impulses. This rise in extracellular dopamine is counteracted by three known mechanisms: (1) rapid diffusion of dopamine from the synapse; (2) reuptake of dopamine by the dopamine transporter which is situated along the nerve cell membrane; and (3) inhibition of further dopamine release by extracellular action of dopamine on the dopamine autoreceptors of the neuron.
Drugs that bind to the dopamine transporter generally increase the extracellular level of dopamine by blocking the transport of dopamine into the neuron, or promoting the release of dopamine. 21, 22 For example, blockade of the dopamine transporter by methylphenidate, or enhanced release of dopamine by dextroamphetamine elevates the extracellular level of dopamine to trigger a cascade of dopamine-receptor-mediated events. These events depend on the dose of methylphenidate or dextroamphetamine and the rate of entry of such drugs into the brain. These two important factors regulate the time-course of the rise in extracellular dopamine, and thereby determine the magnitude of the therapeutic benefit or the stimulant effects and the degree of abuse liability. [23] [24] [25] [26] Stimulant drugs raise extracellular dopamine, but reduce pulsatile dopamine relative to the resting level The normal resting or basal level of extracellular dopamine is approximately 4 nM, [27] [28] [29] and transiently rises at least 60-fold to about 250 nM during a normal nerve impulse. This transiently elevated level of extracellular dopamine falls back to 4 nM, primarily by diffusion 29 but assisted by the dopamine transporter, as illustrated in Figure 3 (A and B).
Dextroamphetamine 22, [30] [31] [32] [33] and methylphenidate, 31, 34, 35 as well as cocaine, 32, 33, 36 all increase the level of extracellular dopamine in the dopamine-rich regions of the brain, as measured directly by means of intracerebral dialysis.
Methylphenidate and cocaine raise the extracellular level of dopamine primarily by blocking the dopamine transporter, thereby preventing the re-entry of dopamine into the neuron. 37 Although dextroamphetamine (ෂ 150 nM) also inhibits the dopamine transporter, this drug directly releases dopamine. 37, 38 Methylphenidate and cocaine do not have this direct releasing action. 37 The increased output of dopamine by stimulants has also been measured indirectly in human volunteers by brain PET* imaging, using the method of ligand displacement from dopamine D2 receptors by endogenous dopamine. 39 Such studies [40] [41] [42] [43] [44] [45] [46] [47] indicate that dextroamphetamine [40] [41] [42] [45] [46] [47] [48] [49] appreciably elevates synaptic dopamine such as to inhibit the binding of various PET ligands to dopamine D2 receptors by 6-48%, while methylphenidate 43 and cocaine 44 result in an inhibition of about 10%, as summarized in Table 1 . These values indicate a considerable increase in the basal resting levels of dopamine in the extracellular synaptic space. 48 However, the imaging method limits the collection of data to 30-60 s intervals, far slower than the rapid ms time-course of nerve-impulse-associated release of dopamine. The PET image, therefore, reflects the time-averaged result of the competition between * Positron emission tomography. endogenous dopamine (resting and pulsatile) and the [ 11 C]ligand. Thus, the PET data listed in Table 1 represent the average net effect of elevated extracellular dopamine arising from an increase in the resting level of dopamine as well as in the pulsatile release of dopamine.
Low doses of stimulant drugs increase the resting level of extracellular dopamine far more than they increase the nerve-impulse-associated pulsatile output of dopamine. This conclusion comes from amperometry methods both in vitro and in vivo, using carbon fiber microelectrodes which are 6-10 m wide. For example, the low dose of 0.5 mg kg −1 dextroamphetamine elevates the basal or resting level of dopamine by six-fold in the living rat brain, 49, 50 but increases the pulsatile or stimulated release or dopamine by only two-fold or less [51] [52] [53] (see Table 2 ). While increasing the spontaneous output of dopamine, low concentrations of dextroamphetamine can even decrease the electrically stimulated output of dopamine in brain slices. 54 In fact, 0.5 mg kg −1 dextroamphetamine given to 23 hyperactive children lowered the spinal fluid level of homovanillic acid, the major metabolite of dopamine, by 34% in direct relation to the clinical improvement of their hyperactive syndrome. 55 By raising the baseline level of extracellular dopamine, therefore, the net effect of the low dose of the stimulant drug is to lower the relative rise in the pulsatile release of dopamine, expressed as a percent rise from the baseline.
At low doses of stimulants, therefore, the elevated resting extracellular dopamine lowers the relative rise (compared to baseline) in the pulsatile release of dopamine by acting on presynaptic dopamine D2 receptors (on the nerve terminal) which in turn inhibits the stimulated release of additional dopamine. 51, 56, 57 Hence, the cellular pharmacology of the stimulant drugs at low doses may be depicted as in Figure 3 . Panels A and B of this figure illustrate that the normal resting level of extracellular dopamine (of the order of 4 nM [27] [28] [29] ) transiently rises 60-fold (to about 250 nM) during a normal nerve impulse. 29 This transiently elevated level of extracellular dopamine falls back to 4 nM in a matter of a few milliseconds, primarily by diffusion 29 but assisted by the dopamine transporter. In the presence of methylphenidate or dextroamphetamine (panels C and D), the dopamine transporter is blocked (step 3) and the resting extracellular level of dopamine rises by about 6-fold, as mentioned above. In turn, the elevated resting level of dopamine acts on the presynaptic dopamine D2 receptors (step 4) to reduce the relative rise in the impulse-triggered release of additional dopamine (step 5) to only two-fold (Table 2) .
At higher doses of dextroamphetamine, above 1 or 2 mg kg −1 , the magnitude of the increase markedly raises the resting level of extracellular dopamine by 14-to 35-fold, 49, 50, 55 while raising the pulsatile output of dopamine by 7-fold. 51, 52 These higher doses are associated with generalized stimulation of the nervous sys- The elevated resting level of dopamine acts on presynaptic dopamine D2 receptors on the nerve terminal (step 2), resulting in an impulse-associated release of dopamine (step 3) which is less than the six-fold rise between A and C, and proportionately less than the percent rise from A to B. This lower differential rise in pulsatile dopamine acts on post-synaptic D2 dopamine receptors to result in less locomotor activity. Higher doses of stimulants markedly elevate the resting level of extracellular dopamine, and result in marked behavioral stimulation which is not overcome by the steps shown here. tem, arising from the very high level of extracellular dopamine at rest and the increased release of dopamine during the nerve impulses. These high levels of resting and pulsatile dopamine cause widespread stimulation of post-synaptic dopamine receptors, overcoming the presynaptic inhibition of further dopamine release.
The anti-hyperactivity action of stimulants is mediated via post-synaptic dopamine D1 and D2 receptors
As just outlined, the enhanced output of dopamine by low doses of stimulant drugs reduces the impulse-associated rise of dopamine, relative to the baseline. That is, the relative rise of dopamine during the impulse is lowered because of this elevated baseline. The smaller pulsatile surge of dopamine would result in less activation of the post-synaptic dopamine D1 and D2 receptors, thereby resulting in reduced psychomotor activity. These psychomotor-controlling dopamine receptors 58 are hypothesized to vary their response in proportion to the relative rise in pulsatile dopamine, but there is not direct experimental work to validate this particular point. For example, the elev- ated extracellular dopamine would occupy more D1 and D2 receptors during rest, reducing or desensitizing these receptors from the dopamine which arrives during the nerve impulses. (One molecular mechanism of such desensitization is based on the current observations that dopamine receptors exist as dimers or oligomers (to be published) which appear to behave similar to the interaction between oxygen and hemoglobin, where the first molecule of oxygen reduces the affinity of hemoglobin to bind the second molecule of oxygen.)
While the steps in Figure 3 may account for the hypolocomotor action of low doses of stimulants, high doses of stimulants cause marked elevations in the resting and pulsatile levels of extracellular dopamine, providing high enough extracellular levels of dopamine to oversaturate and overstimulate postsynaptic dopamine receptors, overwhelming the presynaptic inhibitory action of dopamine. These high levels are associated with hyperdopaminergic somatic, behavioral and psychological signs and symptoms which necessitate lowering the clinical dose.
Although long-term dopamine agonists consistently reduce the density of D2 receptors, [58] [59] [60] [61] the effects of amphetamine, methylphenidate or cocaine on the density of dopamine D2 receptors depend on the experimental conditions used. As mentioned above in connection with Table 1 62 in vivo, but these data do not necessarily reflect changes in the density of D2 receptors.
Consistent with the fact that dextroamphetamine increases the output of dopamine and prolongs the exposure and desensitization of post-synaptic dopamine receptors, long-term administration of dextroamphetamine does lower the density of dopamine D2 Figure 4 The A1 and A2 variants of the dopamine D2 receptor gene, as cut or not cut (at position 15 700 bases) by the restriction enxyme, TaqI. This enzyme cuts the full-length gene to yield fragment A1 with 6600 bases or fragment A2 with 3700 bases. [86] [87] [88] [89] [90] [91] [92] [93] Although it is unclear whether there is an association between the frequency of these fragments and attention deficit hyperactivity syndrome, [86] [87] [88] [89] [90] [91] [92] [93] the coding region of the dopamine D2 receptor itself is identical.
receptors. 63 Paradoxically, however, short-term dextroamphetamine (from 5 min to 24 h before the radioligand) actually increased the binding of [ 3 H]spiperone to D2 receptors in animal brain striata. 61, [63] [64] [65] [66] [67] [68] [69] However, because D2 receptors can exist as monomers or dimers, with spiperone-like molecules preferring the monomer, 70 this apparently paradoxical rise in [ 3 H]spiperone binding to D2 receptors may reflect a rise in the density of D2 monomers following short-term exposure to dextroamphetamine. Altogether, although the dopamine D1 and D2 receptors are important components of the final path for controlling locomotor activity, there is at present no clear relation between the density of dopamine receptors and the immediate clinical action of the stimulants.
In addition to the density of receptors, the functional activity of dopamine receptors must be considered. The dopamine receptors can exist in either a state of high or low affinity for dopamine. 5 The high-affinity state is the functional state for both the D1 and D2 receptors. Thus, by raising the extracellular level of dopamine, the stimulants could alter the balance between the high-and low-affinity states. In fact, early evidence 71, 72 indicates that a single dose of dextroamphetamine (7.5 mg kg −1 ) to rodents reduces the binding of [ 3 H]dopamine to the high-affinity state of D1 receptors (in the presence of 20 nM spiperone to occlude D2 receptors) by 30%. 71 In addition, multiple injections of dextroamphetamine (2.5 mg kg −1 every 4 h over 5 days) results in a 27% reduction in the binding of [ 3 H]N-propylnorapomorphine, 72 a ligand which binds to the high-affinity states of both D1 and D2 receptors, but mostly the latter. These reductions in the proportion of high-affinity states for dopamine at the D1 and D2 receptors reflect a desensitization of these receptors. This process alone, however, is not sufficient to account for a biphasic action of the stimulants on behavior, unless very high concentrations of extracellular dopamine activate both the high-and lowaffinity states of dopamine receptors or alter the cycling between the high-and low-affinity states of the receptors.
In addition, a proportion of post-synaptic dopamine D1 and D2 receptors may be 'spare receptors' and not required for the full action of dopamine. By raising the extracellular dopamine, therefore, stimulant drugs could alter the proportion of spare receptors, but there is no information yet on this point.
The occupancy of the dopamine transporter by the stimulant drugs
Do the clinical concentrations of methylphenidate and dextroamphetamine in plasma correspond to the concentrations which occupy the main clinical target for these medications, the dopamine transporter?
Although there is a wide range of published values for the concentration of methylphenidate which occupies 50% of the dopamine transporter sites in native tissues in vitro,* reasonably consistent values are emerging from work with the cloned dopamine transporter. 74, 75 At present there is only one study 74 which examined all three stimulants (methylphenidate, dextroamphetamine and cocaine) on the cloned dopamine transporter, and a summary of these data is given in Table 3 .
From a clinical point of view, it is important to note that the plasma concentration of methylphenidate in children at the peak action between 1 and 3 h 76 closely matches the concentration which occupies the dopamine transporter, 74 namely, between 20 and 30 nM, as given in Table 3 . This is compatible with the view that the dopamine transporter is the main target for the clinical action of methylphenidate.
The situation with dextroamphetamine is generally similar, because the clinical concentrations of dextroamphetamine in plasma (ෂ 150 nM 77 ) are sufficient to occupy a significant proportion of the dopamine transporters (Table 3) .
Further support that the dopamine transporter is the main target for the stimulant drugs comes from genetic knockout experiments. Mice which are genetically bred without the dopamine transporter do not display increases in dopamine in response to cocaine. 21 Although such animals would presumably not exhibit * From 9.8-34 nM, using [ any locomotor slowing upon administration of low doses of stimulant drugs, this has apparently not yet been directly examined.
In humans, moreover, the onset of clinical symptoms with intravenous methylphenidate or cocaine parallels the onset of occupancy of the dopamine transporter by tracer amounts of [ 11 C]cocaine or [ 11 C]methylphenidate; 78, 79 such occupancy studies have not yet been done using oral methylphenidate. Although these findings generally support the view that stimulant drugs primarily act on the dopamine transporter, such tracer radioligands may also bind to other sites in the brain.
Stimulant drugs and variants of transporters and dopamine receptors
The human dopamine transporter has different forms in different individuals wherein the transporter has between three and 11 copies of a 40-base unit in the noncoding region of the transporter. [80] [81] [82] In addition, it has been reported that there is an association between attention deficit hyperactivity disorder and a variant of the dopamine transporter gene. 83, 84 If this association is supported by additional family linkage studies, it may be possible to identify variants of the dopamine transporter which may have an altered sensitivity to endogenous dopamine. At present, however, no such variations in the coding sequence of the dopamine transporter have been found. Whether such variants in the dopamine transporter exist or not, the stimulant drugs slow down both hyperactive and control individuals. Hence, there is no reason to think at present that such transporter variants, should they exist in the population, would have a significantly different pharmacology with respect to the stimulant drugs.
Although post-synaptic dopamine D1 and D2 receptors are considered to be the major target for response to the stimulant-induced alterations in dopamine release, 85 it is unsettled as to whether variants of the full-length gene for the dopamine D2 receptor are associated with impulsive-addictive-compulsive behaviour. [86] [87] [88] [89] [90] [91] [92] [93] A diagram of the two variations of the fulllength gene for the dopamine D2 receptor is shown in Figure 4 . 86 It may be seen that the single base change is far removed from the coding region of the D2 receptor itself. Hence, the stimulant pharmacology on D2 would be identical for these two variants.
The dopamine D4 receptor, however, has many variations in the human population. 94, 95 One form (with seven 16-amino-acid repeats, termed the D4.7 receptor, as illustrated in Figure 5 ) occurs more frequently in attention deficit hyperactivity disorder. 96, 97 There is a tendency for the D4.7 receptor to be slightly less sensitive to dopamine than the shorter D4.2 receptor, 98 although more research needs to clarify this particular point. If the disease linkage to the D4.7 receptor is confirmed, if the D4.7 receptor is significantly less sensitive to dopamine, and if this receptor turns out to have a central role in the action of stimulant medications, then, according to HHM Van Tol (personal communication, 1997), it may be possible to develop dopamine agonist stimulants which are selective for the dopamine D4 receptor.
Although the present review emphasizes the role of the dopamine system in mediating the anti-hyperactivity action of the methylphenidate and dextroamphetamine, there is considerable evidence that these medications have substantial effects on noradrenergic neurotransmission. [99] [100] [101] Moreover, although the model of stimulant action in this review works best for the brain striatal circuits, this model may need to be modified to encompass the action of extremely low dose effects of methylphenidate, 102 as well as a more elaborate contribution from autoreceptors 103 and the prefrontal cortex. [103] [104] [105] In summary, during normal nerve activity, extracellular dopamine levels transiently rise 60-fold (from 4 nM to 250 nM). At low therapeutic doses (0.2-0.5 mg kg −1 ) to treat attention deficit hyperactivity disorder, stimulant drugs such as methylphenidate and dextroamphetamine reduce locomotion in both humans and animals. The drugs raise resting extracellular levels of dopamine several-fold, but reduce the extent to which dopamine is released with nerve impulses, compared to the impulse-associated release in the absence of the drug. This relatively reduced amplitude of impulse-associated dopamine would result in less activation of post-synaptic dopamine receptors which drive psychomotor activity. In addition, the elevated extracellular dopamine appears to reduce the number of D1 and D2 receptors which are in the functional high-affinity state for dopamine. At higher doses, stimulants produce generalized stimulation of the nervous system, as a result of the very high concentrations of extracellular dopamine at rest, and the markedly increased release of dopamine with nerve impulses. These high levels of resting and pulsatile dopamine cause widespread stimulation of postsynaptic dopamine receptors, overcoming any concomitant presynaptic inhibition of dopamine release.
